– CANADA, Mississauga – Trillium Therapeutics Inc. (NASDAQ: TRIL | TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical industry leader Dr. Catherine Mackey, Ph.D., to its Board of Directors, effective immediately.
“We are excited to welcome Dr. Mackey to our board of directors,” said Lead Director, Paolo Pucci. “Her significant executive experience and expertise leading research and development organizations will be invaluable as Trillium advances its two lead product candidates into a Phase 1b/2 program.”
About Dr. Kitty Mackey
Dr. Mackey has more than 30 years of operating experience in the pharmaceutical and biotechnology sectors. From May 2001 to December 2010, Dr. Mackey served as SVP, Global R&D, and Director, of Pfizer’s La Jolla Laboratories, one of Pfizer’s primary pharmaceutical research and development sites. During her tenure, Pfizer La Jolla delivered a steady-state pipeline of more than two dozen development compounds.
She is currently the chair of the board of directors of Cour Pharmaceutical Development Company, and also serves as a director of AVID Bioservices, Rady Children’s Hospital, and the Rady Children’s Institute of Genomic Medicine. Dr. Mackey previously served as a director of Poseida Therapeutics, GW Pharmaceuticals, YM Biosciences, Evolve Biosystems, Sequenom Inc., and Viventia Bio.
“Trillium is at a critical milestone in its evolution and I am delighted to join the company’s Board as Trillium advances its two highly differentiated CD47 assets into a Phase 1b/2 program,” said Dr. Mackey. “With two drug candidates, planned trials in seven target indications, and multiple drug combinations in patients with hematologic malignancies and solid tumors, Trillium is well-positioned to generate a robust flow of new data over the next couple of years.”
Dr. Mackey received her B.S. and Ph.D. degrees in microbiology and genetics from Cornell University.
About Trillium Therapeutics
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-622 and TTI-621, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.
For more information: https://trilliumtherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.